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Abstract: An urgent demand exists for the development of novel delivery systems that efficiently
transport antibacterial agents across cellular membranes for the eradication of intracellular pathogens.
In this study, the clinically relevant poorly water-soluble antibiotic, rifampicin, was confined within
mesoporous silica nanoparticles (MSN) to investigate their ability to serve as an efficacious nanocarrier
system against small colony variants of Staphylococcus aureus (SCV S. aureus) hosted within Caco-2
cells. The surface chemistry and particle size of MSN were varied through modifications during
synthesis, where 40 nm particles with high silanol group densities promoted enhanced cellular uptake.
Extensive biophysical analysis was performed, using quartz crystal microbalance with dissipation
(QCM-D) and total internal reflection fluorescence (TIRF) microscopy, to elucidate the mechanism
of MSN adsorption onto semi-native supported lipid bilayers (snSLB) and, thus, uncover potential
cellular uptake mechanisms of MSN into Caco-2 cells. Such studies revealed that MSN with reduced
silanol group densities were prone to greater particle aggregation on snSLB, which was expected to
restrict endocytosis. MSN adsorption and uptake into Caco-2 cells correlated well with antibacterial
efficacy against SCV S. aureus, with 40 nm hydrophilic particles triggering a ~2.5-log greater reduction
in colony forming units, compared to the pure rifampicin. Thus, this study provides evidence for the
potential to design silica nanocarrier systems with controlled surface chemistries that can be used to
re-sensitise intracellular bacteria to antibiotics by delivering them to the site of infection.
Keywords: mesoporous silica; nanoparticle; permeability; antibiotics; total internal reflection;
fluorescence microscopy; Caco-2; infection; small colony variants; Staphylococcus aureus
1. Introduction
Harmful pathogens, such as Staphylococcus aureus, have evolved a multitude of evasive and
defensive mechanisms that promote their survival against conventional antimicrobial agents—one of
which is their ability to be internalized within host cells, protecting them from immune responses and
conventional antibiotics [1,2]. Subsequently, intracellular pathogens are the source of several infectious
diseases with limited treatment options and, thus, remain a major pharmaceutical challenge [3,4].
In order to treat pathogens residing in the intracellular environment, antibacterial agents must be
delivered to the site of infection. Conventional antibiotics, such as rifampicin, suffer from low
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solubilities and/or low permeabilities, which restricts their ability to diffuse or be actively transported
across the cellular membrane [5]. Subsequently, it has been estimated that over two-thirds of prescribed
antibiotics are ineffective against intracellular pathogens [6]. Thus, a growing urgency exists for the
development of new classes of antibiotics capable of being efficiently internalized by infected cells.
Intracellular pathogens can reside in an array of host cells, including immune cells, epithelial cells
and bone cells [7–9]. Of increasing complexity with respect to treatment approaches are intracellular
infections that reside within epithelial cells of the gastrointestinal (GI) tract, since physiological
processing throughout the GI tract presents new obstacles for drug delivery [10]. For example,
a wide range of antimicrobial peptides and proteins have been developed in recent years that exhibit
bactericidal activities by disrupting bacterial cell membranes and have subsequently demonstrated
in vitro efficacies in the treatment of intracellular pathogens [11,12]. However, while such biopolymers
present promise for clinical translation in the treatment of some intracellular infections, their application
to bacteria residing in the GI tract is limited due to stability issues, specifically within the harsh enzymatic
and acidic conditions of the gastric environment [13].
An alternative delivery approach with demonstrated efficacy [14] and potential application
for treating intracellular infections residing in the GI tract is to increase the antibacterial activity of
conventional antibiotics by encapsulating them within nanocarriers that readily undergo endocytosis,
thus delivering the antibiotic to the localized site of infection [15,16]. For this to serve as an effective
approach, the nanocarrier system must: (i) have high physicochemical stability within the GI tract,
(ii) protect the antibiotic from burst release prior to cell uptake, (iii) be effectively internalized within
the target cell/s, (iv) release the drug within the intracellular compartments, ideally localizing drug
release to the site of infection, and (v) be non-toxic to all host cells [17].
One such biocompatible nanocarrier system that has been used extensively to deliver drugs
intracellularly, including within intestinal epithelium cells [18–20], and has been widely used for
oral delivery, is that of mesoporous silica nanoparticles (MSN) [21,22]. MSN offer a number of
delivery advantages, including their high physicochemical stability, nanoscale size which promotes
rapid endocytosis by host cells, and ability to confine drugs with varying polarities at high
concentrations [23,24]. Subramaniam et al. [14] recently investigated the ability for MSN, with varying
particle sizes, to be internalized within macrophages for the treatment of small colony variants of
S. aureus (SCV S. aureus). It was established that MSN enhanced the localized rifampicin concentration
within the infected macrophages, which significantly reduced the number of live bacteria present
within the cells and, thus, increased the bactericidal activity of rifampicin. However, macrophages have
distinct uptake mechanisms that promote internalization of foreign bodies, which vary considerably
to epithelial cells. Thus, it is unclear whether this formulation approach will serve as an effective
treatment for eradicating bacteria shielded within epithelial cells, such as Caco-2 cells.
In this study, we investigate the ability for MSN particles, specifically with varying to surface
chemistries and two different particle sizes, to be internalized by Caco-2 cells infected with SCV
S. aureus, which serves as a model system simulating infected intestinal epithelial cells [25]. Hiroshima
mesoporous material (HMM)-type MSN were selected and synthesized for this study, since the
synthesis approach allows for spherical particles with controllable diameters < 100 nm and pore
sizes > 5 nm, thus promoting efficient cell uptake and sufficient drug loading, respectively, when
compared with other conventional MSN types [26–28]. By adopting facile changes to the synthesis
approach, three sets of nanoparticles were developed with varying surface chemistries and particle
sizes to allow for elucidating their role on cellular uptake and antibacterial activity of the encapsulated
antibiotic, rifampicin. The impact of surface chemistry and particle size on the biophysical interaction
with lipid membranes was further investigated using advanced surface-sensitive characterization
techniques, specifically quartz crystal microbalance with dissipation (QCM-D) and total internal
reflection fluorescence (TIRF) microscopy. In doing so, the mechanism of MSN adsorption onto
biologically relevant lipid bilayers was quantified, which allowed for direct comparisons to be made
with cellular uptake and antibacterial efficacy studies. Such biophysical insights derived from this
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study can be harnessed for the optimisation of porous biomaterials in delivering bioactive molecules
to epithelial cells.
2. Materials and Methods
All materials were sourced from Sigma-Aldrich (Castle Hill, NSW Australia; Stockholm, Sweden)
unless otherwise specified.
2.1. Fabrication of Mesoporous Silica Nanoparticles (MSN)
2.1.1. Synthesis of MSN
Mesoporous silica nanoparticles (MSN) were prepared via the synthesis method developed by
Subramaniam et al. [14], using cetyltrimethylammonium bromide (CTAB) as a templating agent,
tetraethyl orthosilicate (TEOS) as a silica source, hexane as the hydrophobic component and L-lysine
as a catalyst. CTAB (800 mg) was mixed with L-lysine (180 mg) prior to forming an emulsion with
Milli-Q (248 g) and hexane (60 g for 40 nm particles; 120 g for 80 nm particles), via vigorous stirring
for 1 h at 70 ◦C. TEOS (8 g) was added to the emulsion, which continued stirring for 20 h at the same
temperature. The suspension was cooled at room temperature and oven dried for 3 h at 80 ◦C. In this
study, the surfactant was removed either via (i) calcination, by increasing the temperature from room
temperature to 650 ◦C for 8 h and maintaining this temperature for a further 6 h, to create ‘calcined
MSN’ (MSNc); or, (ii) solvent extraction, where the dried powder was resuspended in a mixture of
90 mL of methanol and 10 mL of 12 M HCl and left to reflux at 70 ◦C overnight, to create ‘extracted
MSN’ (MSNe). The suspension was centrifuged at 29,060 g for 10 min. After washing with methanol,
the particles were refluxed again to ensure all of the organic material was removed. After centrifugation
and washing, the particles were oven dried.
2.1.2. Rhodamine B Loading into MSN
MSN were dispersed in Milli-Q at a concentration of 1 mg/mL via sonication. Rhodamine B stock
(1 mg/mL in Milli-Q) was added to the dispersed particles at a ratio of 1:100 and left to stir for 2 h.
The particles were collected by centrifugation at 29,060 rcf for 10 min and washed three times with
Milli-Q to remove any rhodamine B freely dispersed within the aqueous media (i.e., not encapsulated
within MSN).
2.1.3. Rifampicin Loading into MSN
MSN (2 mg) were added to 4 mg rifampicin solution in methanol (2 mL). The suspension was stirred
at 500 rpm for 24 h, subsequently centrifuged, washed and oven dried overnight. Non-encapsulated
rifampicin within the supernatant was recovered and quantified via UV–Vis spectroscopy at a
wavelength of 254 nm to determine the loading capacity and encapsulation efficiency, as previously
described by Subramaniam et al. [14].
2.2. Physicochemical Characterization of MSN
2.2.1. Particle Sizing and Structure
MSN were suspended in ethanol at a concentration of 1 mg/mL via sonication for 1 h. Samples
(5 µL) were transferred to copper grids and left to air dry for > 30 min to allow for complete ethanol
evaporation. Transmission electron microscopy (TEM) analysis was performed using a JEM-1200 EX II
(JEOL) at 120 kV accelerating voltage.
2.2.2. Nitrogen Adsorption/Desorption Isotherms
Nitrogen isotherms were measured at liquid nitrogen temperature using a Micromeritics TriStar II
volumetric adsorption analyzer (Micromeritics Instrument Corporation, GA, USA). Prior to measuring,
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the MSN were outgassed for 3 h at 200 ◦C. The Brunauer–Emmett–Teller (BET) equation was used to
calculate the surface area from the adsorption data obtained in the relative pressure range of 0.05 to 0.3.
The total pore volume was calculated from the amount of gas adsorbed at 0.91 (P/P0) and the pore size
distribution curves were derived using the Barrett–Joyner–Halenda (BJH) method.
2.2.3. Thermogravimetric Analysis (TGA)
The relative degree of surfactant remaining within untreated MSN (MSNut, i.e., no surfactant
removal), MSNc and MSNe was determined by heating the MSN at a scanning rate of 10 ◦C/min
from 20 to 600 ◦C, under nitrogen purging. CTAB completely decomposed by 500 ◦C, whilst the
silica remained thermally stable under these conditions. The amount of CTAB remaining within the
MSN was determined by the weight loss accounting for trace amounts corresponding to residual
water moisture.
2.2.4. Fourier Transform Infra-Red Attenuated Total Reflection (FTIR-ATR) Spectroscopy
Infrared spectra of CTAB, MSNut, MSNc and MSNe were recorded using a Perkin Elmer, Spectrum
Two spectrometer (Waltham, MA, USA) using a universal ATR over 600–4000 cm−1.
2.3. Quartz Crystal Microbalance with Dissipation (QCM-D) Studies
QCM-D measurements were performed on silicon dioxide-coated QSX 303 QCM-D sensors
mounted in a Q-Sense E4 system (Biolin Scientific AB, Gothenburg, Sweden). The sensor and solution
chamber were maintained at 37 ± 0.1 ◦C for the duration of the experiments and the third harmonic was
recorded. The sensors were first flushed with TRIS buffer (125 mM NaCl (Sigma Aldrich, Stockholm,
Sweden), 10 mM TRIS (Merck, Stockholm, Sweden), 1 mM Na2EDTA (Sigma Aldrich), adjusted
to pH = 7.4 using HCl) at a flow rate of 50 µL/min. Supported lipid bilayer (SLB) formation was
monitored for ~10 min by incubating 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; Avanti
Lipids Inc., Alabaster, AL, USA) vesicles (0.1 mg/mL in TRIS buffer) at continuous flow. Following
rinsing, the SLB was exposed to various MSN (concentration = 105 particles/mL in TRIS buffer), while
concurrently monitoring changes in frequency (∆f) and dissipation (∆D).
2.4. Total Internal Reflection Fluorescence (TIRF) Microscopy Studies
2.4.1. Preparation of Semi-Native Lipid Vesicles
Synthetic vesicles were prepared using a lipid film hydration and extrusion method, where POPC
was dissolved in chloroform, which was then evaporated at the bottom of a round bottom flask under
vacuum for > 2 h to remove any trace of the solvent. POPC was rehydrated with TRIS buffer for at
least 3 h to obtain a lipid concentration of 1 mg/mL. The vesicle solution was extruded through a 50 nm
polycarobante membrane (Whatman, Maidstone, UK) 11 times using a mini extruder (Avanti Lipids
Inc., Alabaster, AL, USA). Extruded vesicles were stored at 4 ◦C until use.
Native membrane vesicles (NMVs) were prepared using a SF9 cell line via a detergent-free
preparation protocol, as previously described by Pace et al. [29,30]. NMVs were mixed with POPC
vesicles at a ratio of 1:5 to form semi-native membrane vesicles (sNMV).
2.4.2. Preparation of Fluorescent Tracer Vesicles
Tracer vesicles were prepared by mixing 99 mol% POPC with 1 mol% 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-PE; Avanti Lipids Inc., Alabaster,
AL, USA) and following the lipid film hydration and extrusion method.
2.4.3. Formation of a Semi-Native Supported Lipid Bilayer (snSLB)
Total internal reflection fluorescence (TIRF) microscopy was conducted on an inverted Eclipse
Ti-E microscope (Nikon Corporation, Minato City, Japan) that was equipped with a Perfect Focus
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System (PFS), a CFI Apo TIRF 100x oil objective (NA 1.49), a high-pressure mercury lamp and an
Andor Neo SCC-01322 sCMOS camera (Andor Technology, Belfast, UK). A snSLB was formed on a flat
glass substrate (0.13–0.16 mm thickness). sNMV vesicles were incubated with NBD-PE tracer vesicles
at a ratio of 1/100, with 10 µL added to custom made PDMS wells with a volume of ~ 50 µL. A FITC
filter set (Semrock, Sandwich, IL, USA) was used for visualising the snSLB or POPC/NBD-PE vesicles.
snSLB formation was confirmed by observing fluorescent recovery after photobleaching (FRAP), i.e.,
by bleaching the NBD-PE tracer lipids with a Kr-Ar mixed gas ion laser (Stabilite 2018, Spectra-Physics
Lasers, Mountain View, CA, USA) at a wavelength of 531 nm. The diffusivity of NBD-PE within
the lipid membrane was determined using a custom written analysis software in MATLAB R2017B
(MathWorks, 2017, Natick, MA, USA), as described by Jonsson et al. [31] The snSLB was then subjected
to rinsing with TRIS buffer until the majority of unbound vesicles were removed.
2.4.4. Monitoring of MSN Adsorption onto snSLB
A volume of 10 µL of rhodamine-labelled MSN dispersion (concentration = 105 particles/mL)
was added to the rinsed snSLB, and adsorption was monitored with TIRF microscopy, imaging at
10 frames per second for 2 min, using a rhodamine filter set (TRITC, Semrock, Sandwich, IL, USA).
The number of particles adsorbed onto the snSLB was quantified using a custom written analysis
software in MATLAB R2017B (MathWorks, 2017, Natick, MA, USA) and the fluorescent intensity of
MSN aggregates was analysed using ImageJ (Fiji, 2017, Lexington, KY, USA) [32].
2.5. In Vitro Cellular Uptake Studies
2.5.1. Cellular Uptake of MSN Particles with Flow Cytometry
The cellular uptake of rhodamine B-labelled MSN was investigated using fluorescence-activated
cell sorting (FACS), in which the Caco-2 cells were seeded at 5 × 104 cells/mL in Dulbecco’s Modified
Eagle’s Medium (DMEM) medium. The cells were incubated for 24 h at 37 ◦C with 5% CO2 for cell
attachment. Following incubation, the medium was removed, and the cells were treated with pure
rhodamine B and various rhodamine B-MSN (rhodamine B concentration of 50 µg/mL) in DMEM.
Following incubation for 4 h, the supernatant was discarded, and the cells were gently washed 3×with
ice-cold PBS to remove any extracellular particles. Following rinsing, the cells were centrifuged at 600 g
for 5 min to obtain the cell pellet. The supernatant was discarded, and the pellet was resuspended in
2% paraformaldehyde (PFA) and incubated for 15 min at room temperature, prior to centrifugation and
washing in triplicate. The rinsed cells were subsequently transferred into FACS tubes. The fluorescence
was analysed using Accuri C6 Plus flow-cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
2.5.2. Cellular Uptake of MSN Particles with Confocal Microscopy
Confocal fluorescence imaging was performed with a Zeiss Elyra PS-1 Super Resolution Microscope
(Oberkochen, Germany), using a white-light laser source and a 60× objective. Briefly, Caco-2 cells
(seeding density of 1 × 105 cells/well) were incubated with rhodamine B-MSN at a concentration of
50 µg/mL in DMEM. After 4 h incubation, the supernatant was discarded, and the cells were washed
3x with PBS and fixed with 4% paraformaldehyde. Before imaging, the nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI) and imaged at an emission wavelength of 461 nm (excitation
wavelength 358 nm) and the cell membrane was stained with Alexa-488 at an emission wavelength of
525 (excitation wavelength of 490 nm) which appeared as blue and green, respectively.
2.6. In Vitro Cell Viability Studies
An intracellular infection assay was performed in Caco-2 cells by modifying a method developed
by Clemens et al. [33]. Caco-2 cells were seeded at 1 × 105 cells/mL and incubated for 24 h (37 ◦C,
5% CO2). SCV S. aureus overnight cultures were prepared and diluted to a multiplicity of infection
(MOI) of 10:1. After centrifugation of the bacterial suspension (600 g, 10 min, room temperature),
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the supernatant was carefully discarded and the pellet was redispersed in DMEM media. DMEM
inoculum (1 mL) was added to the cells and incubated for 1 h. Following incubation, the cells were
rinsed 3× to remove any extracellular bacteria. Confocal imaging was used to confirm the presence of
SCV S. aureus within the Caco-2 cells, by staining both the bacteria and cell nucleus with DAPI and the
cell membrane with Alexa-488.
Infected Caco-2 cells were incubated with 1 mL of fresh serum-free DMEM containing either
rifampicin or rifampicin-loaded MSN at a rifampicin concentration of 0.5 µg/mL. Following a 4 h
incubation, the medium was removed, and the cells lysed were by 0.1% Triton-X in PBS. The cells were
then transferred to Eppendorf tubes, serially diluted, and plated on Tryptic Soy Agar (TSA) for 15 h at
37 ◦C. To confirm the number of bacteria in the inoculum, serial dilutions of the DMEM inoculum were
also plated on TSA.
2.7. Statistical Analysis
The experimental data were analysed statistically using a Student’s t-test (unpaired). Values are
reported as the mean ± standard deviation, and the data were considered statistically significant when
p < 0.05.
3. Results and Discussion
3.1. Synthesis and Characterization of MSN
Hiroshima mesoporous material (HMM)-type mesoporous silica nanoparticles (MSN) were
synthesised with varying particle sizes and hydrophilicities by varying the organic solvent concentration
and surfactant extraction process (i.e., calcination or solvent extraction), respectively (Figure 1).
Transmission electron micrographs revealed that spherical mesoporous particles were fabricated with
mean particle sizes of 47.0 ± 7.0 nm (MSN40c and MSN40e) and 84.1 ± 17.4 nm (MSN80c) (based on
imaging analysis with Fiji ImageJ [32]) and with mean pore diameters of 11.7 and 7.46 nm (based
on BJH pore size distribution analysis; Supplementary Materials Figure S1), respectively (Table 1).
ATR-FTIR was performed to validate the removal of the cytotoxic templating surfactant, CTAB [34,35],
from the MSN, which also highlighted key differences in the surface chemistry of MSN treated with
solvent extraction and calcination (Figure 1D,E). Evidence of CTAB removal from both calcined and
solvent-extracted MSN was displayed through the absence of the C–H stretching of methylene groups
at ~2800 cm−1. In contrast, untreated MSN (i.e., no surfactant removal; MSNut) clearly displayed the
C–H stretching associated with the methylene groups in CTAB. However, TGA demonstrated that
CTAB was not completely removed from the treated MSN, with a minor fraction (< 1 wt%) of CTAB
remaining after calcination and extraction (Figure 1G).
While no significant differences were observed with respect to the zeta potential of MSN
(Table 1), differences in IR spectra highlighted variations in surface chemistry between calcined and
solvent-extracted MSN, specifically with regards to the increased level of hydroxyl/silanol group
stretching at ~3500 cm−1 for the solvent-extracted MSN (MSN40e). TGA further confirmed the presence
of additional -OH groups in MSN40e, compared to MSN40c and MSN80c, where -OH groups were
shown to decompose at ~500 ◦C (Figure 1F,G). This is in agreement with previous studies that have
shown that calcination of mesoporous silica results in the condensation of Si–OH bonds, resulting in a
higher ratio of Si–O–Si bonds [36–38]. In contrast, solvent extraction has been shown to be a suitable
method of surfactant removal that maintains a high silanol group density on the mesoporous silica
surface, thus maintaining the hydrophilicity and potential biocompatibility of the silica particles [39–42].
Rifampicin loading capacities were shown to be dependent on MSN size and surface chemistry, with
drug loading increasing as a function of increasing particle size and hydrophobicity (Table 1). BJH pore
size distribution analysis revealed that the pore volume of MSN40 was 1.6-fold greater than MSN80,
with both particle sets having equivalent specific surface areas (Supplementary Materials Figure S1).
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Since drug loading was greatest in MSN80c, it can be assumed that loading was more dependent on
particle size and hydrophobicity, rather than pore volume.
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Table 1. Physicochemical properties of MSN.
Particle
Surfactant
Extraction
Protocol
Mean
Particle
Size (nm)
Mean Pore
Width (nm)
Specific Pore
Volume
(cm3/g)
Specific
Surface
Area (m2/g)
Zeta
Potential
(mV)
Drug
Loading
(% w/w)
MSN40e Solvent extraction 47.0 ± 7.0 11.7 1.30 483 −15.1 ± 5.4 28.9
MSN40c Calcination 47.0 ± 7.0 11.7 1.30 483 −13.6 ± 6.3 33.6
MSN80c Calcination 84.1 ± 17.4 7.46 0.81 460 −14.9 ± 4.7 38.2
3.2. Cell Viability a d Caco-2 Uptake of MSN
Cytotoxicity scree ing of MSN was performed using the MTT assay in Caco-2 cells, where
MSN exhibited cell viability ≥ 80% at concentrations of up to 2.5 × 104 particles/mL (Figure 2A).
Cellular survival of 80% is considered the accepted threshold for cell viability [43] and, thus, MSN
at concentrations ≤ 2.5 × 104 particles/mL can be considered non-toxic. At 5.0 × 104 particles/mL,
MSN40e triggered a cellular viability of 62.6 ± 16.5% an can therefore be considered marginally toxic
at this con entration. This could be a tributed to either (i) a higher density of silanol groups pr sent on
MSN40e, compared to MSN40c and MSN80c, since silanol groups have been shown t interact with
cellular membrane components, triggering cell lysis and death [44–47], or (ii) increased particle uptake
for MSN40e (Figure 2B) and, thus, increased exposure to CTAB residues within the MSN. However,
since all particle concentrations used i the cellular uptake and intracellular infection assays were
below 2.5 × 104 particles/mL, the MSN can be safely considered non-toxic to the Caco-2 cell line.
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The intracellular uptake of S particles into Caco-2 cells as observed by encapsulating the
poorly per eable dye, rhoda ine B, into the porous cavities, for quantification using flo cyto etry
(Figure 2B) and qualitative assessment using confocal fluorescence microscopy (Figure 2C) [48]. For all
MSN, the fluorescence intensity associated with cellular uptake was significantly greater than for
the rhoda ine B solution, hich only achieved 1.2 ± 0.4 uptake into aco-2 cells, thus indicating
that rhoda ine B is incapable of permeating the cell membrane through diffusion or endocytosis.
In contrast, MSN particles achieved > 15% cell internalization, demonstrating their ability to be
endocytosed by the aco-2 cells. o significant difference as observed for the uptake bet een the
two groups of calcined MSN, with MSN40c and MSN80c exhibiting 15.1 ± 3.9% and 21.9 ± 3.2% uptake,
respectively. This highlights that varying the MSN size from ~40 to ~80 nm does not significantly alter
uptake into Caco-2 cells. Previous in vitro studies have highlighted that maximum cellular uptake is
achieved within the 10–100 nm size range, since nanoparticles are capable of recruiting and binding to
a sufficient number of membrane receptors at this particle diameter to drive the membrane-wrapping
and pinocytic process [49–52].
MSN40e exhibited enhanced Caco-2 uptake in contrast to both the dye solution and the calcined
MSN, with 36.9 ± 4.6% of particles being internalized after 4 h incubation (Figure 2B). The contrasting
ability for MSN prepared via solvent extraction, versus calcination, was further highlighted using
confocal microscopy, where dense areas of rhodamine B (red regions) surrounded the nucleus (blue
regions) of the Caco-2 cells (Figure 2C). Comparatively, only a minor fraction of dye can be observed
within the cells treated with MSN40c. This is in accordance with previous studies that have highlighted
that an increase in silanol group density drives the interaction between silica nanoparticles and the cell
membrane, thus triggering an increase in cellular uptake [46,53]. However, a fine balance exists between
increasing cellular uptake and limiting cytotoxicity of MSN, since increasing silanol concentrations
also triggers a reduction in cell viability (Figure 2A) [46].
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3.3. Biophysical Analysis of MSN Adsorption onto Biologically Relevant Lipid Bilayers
Quartz crystal microbalance with dissipation (QCM-D) was used to qualitatively assess the
impact of MSN surface chemistry and size on their interactions with biologically relevant supported
lipid bilayers in order to identify possible differences in the cellular uptake behavior of each MSN.
By assessing changes in frequency, f, and dissipation, D, it is possible to deduce relative changes in
the adsorption of species on a supported lipid bilayer (SLB) [54]. Evidence of SLB formation on the
planar silica surface was indicated at ~4–5 min for each sample, whereby a decrease in f and increase
in D due to POPC vesicle adsorption was followed by an increase in f and decrease in D caused by
vesicle rupturing and bilayer formation (Figure 3A). The final ∆f and ∆D of ~−27 Hz and 0.1 × 10−6
(third overtone), respectively, is consistent with previous findings [29,30]. After rinsing, the SLB was
exposed to MSN dispersions, where adsorption of MSN was evidenced by rapid decreases in f and
increases in D due to the viscoelastic nature of nanoparticle adsorption (at t ≈ 10 min). After 3 min
adsorption, the change in frequency and dissipation plateaued for MSN40e, indicating that the SLB
was likely saturated with silica nanoparticles. In contrast, for calcined particles, f and D continue to
decrease and increase, respectively, in a time-dependent manner until the completion of the experiment,
indicating that a highly viscoelastic layer of MSN adsorbs onto the SLB surface. Changes in frequency
and dissipation were greatest for MSN80c, which can be attributed to adsorption of particles twice the
size of MSN40.
Total internal reflection fluorescence microscopy was used to further elucidate the different MSN
adsorption mechanisms on lipid bilayers. To achieve this, a semi-native supported lipid bilayer (snSLB)
composed of 20% w/w native membrane vesicles was adsorbed onto a planar silica surface, since this
presents a more accurate mimic for the cellular membrane due to the presence of native lipids, proteins
and carbohydrates. TIRF microscopy operates by illuminating a sample at an angle of incidence that
triggers light to internally reflect at the interface between a material with varying refractive indices
(known as the critical angle) [55]. The evanescent wave that forms as a result of total internal reflection
decays exponentially into the material with a lower refractive index (in this case, the sample) in a
distance-dependent manner [56]. Ultimately, this allows the depth of penetration of the evanescent
wave to be limited to ~100–200 nm from the glass substrate surface, allowing for the events at the
substrate-supported lipid membrane to be monitored [54]. For this application, TIRF microscopy was
harnessed to discriminate and quantify only the MSN that adsorbed to the snSLB, allowing for the
derivation of new understanding with regards to the impact of particle size and surface chemistry on
membrane adsorption.
The formation of a snSLB was first achieved by depositing semi-native membrane vesicles, labelled
with a fraction of tracer vesicles containing NBD-PE (1 mol%), onto a smooth, hydrophilic silica surface,
as previously demonstrated by Pace et al. [29,30]. Semi-native membrane vesicles were used in this
study, since the presence of membrane proteins and carbohydrates and native lipids serves as a better
mimic for real cell membranes [29,30]. The presence of a small fraction of dye-labelled lipids allowed
for real-time monitoring of vesicle adsorption and rupturing, and the subsequent bilayer formation.
Fluorescent recovery after photobleaching (FRAP) was performed to validate complete formation of a
mobile and intact snSLB (Supplementary Materials Figure S2) [31]. After washing excess membrane
vesicles from the bulk media, the snSLB was incubated with rhodamine-loaded MSN and adsorption
was monitored via TIRF (Figure 3D–F).
Incubation of the snSLB with MSN40e revealed a time-dependent increase in the number of
particles that firmly attached to the lipid bilayer surface, until a maximum of ~610 particles/100 µm2
was reached (Figure 3B). After this point, a decrease in the number of counted particles attached to
the surface was realised. It must be noted that the analysis approach employed cannot discriminate
between individual nanoparticles once aggregated on the membrane surface. That is, an aggregate of
many MSN is counted as one particle. Subsequently, it can be assumed that the decrease in the number
of counted particles after 100 s was not due to particle desorption, but rather particle aggregation of the
individual MSN40e/small clusters on the snSLB surface. Thus, it is hypothesised that the snSLB surface
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became saturated with individual MSN40e/small aggregates, which then continued to aggregate as
additional MSN40e diffuse towards the surface, triggering a reduction in the analysed number of
particles attached to the surface.
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The aggregation of MSN was increasingly evident for MSN40c and MSN80c, which both exerted
complex particle adsorption profiles, whereby increases in particle adsorption were followed with rapid
decreases in particle counts (Figure 3B). Since the maximum number of counted particles/aggregates
adsorbed onto the snSLB surface was reduced for the calcined MSN samples, it does not indicate
that fewer individual MSN particles diffused to the surface, but rather the more hydrophobic MSN
had an increased propensity for particle aggregation. These findings correlate well with QCM-D
analysis, whereby the continual decrease in f and increase in D can be attributed to the formation of
large aggregates on the SLB surface. Interestingly, evidence of MSN40e aggregation on the SLB is not
apparent for MSN40e during QCM-D experiments, which suggests that aggregation may be influenced
by the flow of media (QCM-D was performed under flow conditions, whereas TIRF was static) or the
presence of proteins and carbohydrates within the SLB. To further indicate aggregation on the snSLB
surface, analysis of adsorbed MSN fluorescence intensity (If) highlighted an increase in mean intensity
for both calcined MSN, compared to MSN40e (Figure 3C). Since fluorescence intensity has been shown
to scale with particle size [57], it can be concluded that MSN40c and MSN80c formed significantly
larger aggregates on the snSLB surface, compared to MSN40e, which is hypothesised to be driven by
hydrophobic forces between individual nanoparticles (Figure 3G).
The increased aggregability of MSN40c and MSN80c correlates well with a reduction in Caco-2
cell uptake, since the particle size presented to the cell membrane was expected to be greater than the
individual particles, thus exceeding the size required for pinocytosis (< 500 nm) [58] and limiting the
interaction between the MSN surface and cell membrane receptors that are responsible for driving
endocytic uptake [59,60]. Previous studies have highlighted that MSN uptake into epithelial cells, such
as Caco-2 cells, is highly limited by their ability to remain monodispersed and avoid aggregation in
biological fluid [22]. While these studies have not been performed in biological fluid and are therefore
not ideal replicates for simulating particle uptake in vivo, the biophysical interactions observed in this
study suggest that the propensity for nanoparticle aggregation between calcined MSN may retard
their uptake into epithelial cells, through endocytic pathways, to a greater degree than MSN prepared
through solvent extraction. It is important to note that further studies characterizing endocytosis
pathways, through receptor knockdown approaches, are required to fully elucidate the differences in
uptake between the various MSN.
3.4. Antibacterial Efficacy of Rifampicin-Loaded MSN against Intracellular Pathogens
Caco-2 cells were infected with small colony variants of S. aureus (SCV S. aureus) to serve
as an intracellular infection model for this study, since increasing evidence is indicative of these
subpopulations existing as a problematic source of infection due to their ability to survive within the
intracellular environment of mammalian cells, including within the GI tract [61–63]. SCV S. aureus
replicate slowly, creating subpopulations that are 10-fold smaller and phenotypically different compared
to the parent strain, which is hypothesised to be a driving force for their intracellular internalization
and clinically challenging nature [64]. Unlike their parent strains, SCV acquire two distinct metabolic
characteristics, which leads to phenotypic differences, such as defects in electron transport and
reduced energy (ATP) usage, triggering the slower growth and smaller colony formation [64,65].
Here, the intracellular internalization of SCV S. aureus was confirmed and visualised using confocal
fluorescence imaging, as shown in Figure 4A.
The rifampicin concentration used throughout the intracellular efficacy assay was 0.5 µg/mL,
which was equivalent to 4-fold greater than the Minimum Inhibitory Concentration (MIC) of SCV
S. aureus (determined previously to be 0.125 µg/mL) [16]. Infected Caco-2 cells treated with a
rifampicin solution showed only a minor reduction in the number of colony forming units (CFU)
of SCV S. aureus, after 4 h incubation, which was determined to be statistically insignificant to the
control group (i.e., no treatment) (Figure 4B). In doing so, this further validated the inability for
rifampicin to permeate the cell membrane and be internalized within Caco-2 cells, therefore, exerting
limited efficacy in the reduction of intracellular pathogens, as demonstrated previously for infected
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macrophages [14,16]. In contrast, treatment of infected Caco-2 cells with all rifampicin-loaded MSN
resulted in a statistically significant decrease in SCV S. aureus CFU, when compared to the control
group (Figure 4B). Rifampicin-loaded MSN40e revealed the greatest antibacterial activity, with a
> 2-log reduction in CFU (i.e., ~5 × 106 CFU/mL reduced to ~5 × 104 CFU/mL), which equates
to an extermination of > 99.9% of intracellular pathogens. It must be noted that previous studies
have highlighted that rifampicin release from MSN prior to cellular internalization is minimal [14],
and therefore, the enhanced antibacterial efficacy is attributed to enhanced localized concentrations of
rifampicin at the site of infection. Furthermore, while pore volume and diffusional path length have
been shown to impact on the transport of bioactive molecules to and from porous silica particles [66],
the differences in these two parameters are minimal in this study, and are therefore not considered to
be major factors in controlling rifampicin release.
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Figure 4. (A) Laser scanning confocal fluorescence micrographs of SCV S. aureus-infected Caco-2 cells.
SCV S. aureus and nuclei were labelled with DAPI (magenta) and the cell membrane was labelled with
Alexa-488 (cyan). Intracellular pathogens are highlighted by the arrow. (B) Efficacy of the following
rifampicin formulations in the reduction of intracellular SCV S. aureus within Caco-2 cells: rifampicin
solution (g ey bar), MSN40e (pink bar), MSN40c (green bar), and MSN80c (pu ple bar), relative to a
control group (i.e., no treatment; black bar). (C) Colony forming units of intracellular pathogens as a
function of cellular uptake of each formulation (from data already presented).
Importantly, antibacterial efficacy log-linearly correlated with cellular uptake of formulations in
Caco-2 cells. Thus, this highlights that the improved internalization of MSN translated to an increased
antibiotic concentration localized at the site of pathogen confinement; thus, increasing the susceptibility
of bacteria to rifampicin. This is in agreement with p evious studies that have shown that increasing
antibiotic concentrations within macrophages infected with SCV S. aureus also leads to an increase in
the extent f pathogen eradication [14,16]. Furthermore, this suggests that surface chemistry i a more
important factor for controlling drug delivery into Caco-2 cells.
Ultimately, this study provides further preclinical proof of concept and reveals new opportunities
for repurposing conventional antibiotics, through their encapsulation within nanocarrier systems that
are known to be efficiently internalized within infected cells, in order to increase their antibacterial
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activity against pathogens that shield themselves within the intracellular environment. Moreover, it is
stipulated that more advanced surface modifications should be applied to MSN to optimise cellular
uptake and antibacterial efficacy, while limiting cytotoxicity. By attributing focus to optimising this
antibiotic delivery approach in key infection models and by validating this formulation approach
within in vivo intracellular infection models, it is expected that repurposing antibiotics in such a
manner will reduce the clinical dose required to effectively kill intracellular pathogens.
4. Conclusions
Mesoporous silica nanoparticles with varying surface chemistries and particle sizes were shown
to be effective vehicles for delivering the antibacterial drug, rifampicin, to epithelial cells infected
with S. aureus. For the particle sizes tested (~40 and ~80 nm), surface chemistry was shown to be the
most significant regulator of MSN uptake, with more hydrophilic particles (prepared using solvent
extraction) demonstrating a > 2-fold increase in Caco-2 cell uptake, compared to calcined MSN.
QCM-D and TIRF microscopy revealed that calcined MSN had an increased tendency to aggregate
on biologically relevant lipid membranes, which was expected to delay particle uptake through
endocytic pathways. The efficacy of rifampicin-loaded MSN correlated well with cellular uptake
studies, with hydrophilic MSN exerting the greatest antibacterial activity, reducing SCV S. aureus
colony forming units in Caco-2 cells by ~2.5-fold. Thus, this study highlights the ability to regulate
the antibacterial efficacy of rifampicin-loaded MSN through simple synthesis modifications, which
ultimately alter the uptake mechanisms within epithelial cells. However, to assess the efficacy of this
treatment approach further, future focus should be attributed to developing intracellular infection
animal models and comparing/correlating in vitro performance with in vivo findings in an attempt to
translate antibacterial formulations to the clinic.
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